Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants vs. Warfarin in Japanese Patients With Atrial Fibrillation

Bleeding Risk Related to Upper Gastrointestinal Endoscopic Biopsy in Patients Receiving Antithrombotic Therapy: A Multicenter Prospective Observational Study

“…Of those, antiplatelet drugs such as low-dose aspirin and clopidogrel are used for prevention of cerebrovascular disease and coronary arterial disease 1, 2, 3, 4. On the other hand, anticoagulant drugs, including warfarin and direct oral anticoagulants (DOACs) are given for a variety of clinical conditions, such as prevention of recurrent venous thromboembolism and stroke in patients with atrial fibrillation 5, 6, 7, 8. Thus, antithrombotic agents have been commonly used in recent years as both primary and secondary drugs to prevent cerebrovascular and coronary diseases in the expanding elderly population.…”

Novel Compression Tool to Prevent Hematomas and Skin Erosions After Device Implantation

“…9,12 Both anticoagulation therapy including warfarin or NOAC and antiplatelet therapy, comprising clopidogrel and/or aspirin, was also continued even in patients receiving triple therapy. 13, 14 Patients were instructed to avoid extending the ipsilateral shoulder during physical activity, 10 but otherwise were allowed to walk around the ward immediately after CIED implantation. Actually, most of the patients stayed in bed on the day of operation, because of anxiety.…”

Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?

“…21 These results also suggest that the Japanese population were patients with high bleeding risk and they are not receiving optimal anticoagulation treatment. Major bleeding and intracranial bleeding rates with rivaroxaban in the Japanese population subanalysis of ROCKET-AF tended to be lower compared with the warfarin group but the difference was less than in the Caucasian population 22 and the benefit of rivaroxaban in the Japanese elderly population is unclear. 23 The HAS-BLED score has been validated in Caucasian and Japanese populations, 11,12 and also in younger patients undergoing ECV.…”